Systemic Treatment of Metastatic/Recurrent Uterine Leiomyosarcoma: A Changing Paradigm

Systemic Treatment of Metastatic/Recurrent Uterine Leiomyosarcoma: A Changing Paradigm is organized by Society for Translational Oncology (STO).

Accreditation:
The Society for Translational Oncology designates this journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Learning Objectives:
• Discuss uterine leiomyosarcoma (uLMS), the current agents that have been studied in uLMS and their outcomes, and the ongoing clinical trials.